215 related articles for article (PubMed ID: 29884296)
1. A new descriptor via bio-mimetic chromatography and modeling for the blood brain barrier (Part II).
Kouskoura MG; Piteni AI; Markopoulou CK
J Pharm Biomed Anal; 2019 Feb; 164():808-817. PubMed ID: 29884296
[TBL] [Abstract][Full Text] [Related]
2. Partial least square and hierarchical clustering in ADMET modeling: prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands.
Nikolic K; Filipic S; Smoliński A; Kaliszan R; Agbaba D
J Pharm Pharm Sci; 2013; 16(4):622-47. PubMed ID: 24210068
[TBL] [Abstract][Full Text] [Related]
3. Combined computational-experimental approach to predict blood-brain barrier (BBB) permeation based on "green" salting-out thin layer chromatography supported by simple molecular descriptors.
Ciura K; Belka M; Kawczak P; Bączek T; Markuszewski MJ; Nowakowska J
J Pharm Biomed Anal; 2017 Sep; 143():214-221. PubMed ID: 28641198
[TBL] [Abstract][Full Text] [Related]
4. Current State and Future Perspectives in QSAR Models to Predict Blood- Brain Barrier Penetration in Central Nervous System Drug R&D.
Morales JF; Montoto SS; Fagiolino P; Ruiz ME
Mini Rev Med Chem; 2017; 17(3):247-257. PubMed ID: 27739359
[TBL] [Abstract][Full Text] [Related]
5. Computer Assisted Models for Blood Brain Barrier Permeation of 1, 5-Benzodiazepines.
Dhavale RP; Choudhari PB; Bhatia MS
Curr Comput Aided Drug Des; 2021; 17(2):187-200. PubMed ID: 32003700
[TBL] [Abstract][Full Text] [Related]
6. Correlation of blood-brain penetration using structural descriptors.
Katritzky AR; Kuanar M; Slavov S; Dobchev DA; Fara DC; Karelson M; Acree WE; Solov'ev VP; Varnek A
Bioorg Med Chem; 2006 Jul; 14(14):4888-917. PubMed ID: 16697202
[TBL] [Abstract][Full Text] [Related]
7. Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters.
Mensch J; Jaroskova L; Sanderson W; Melis A; Mackie C; Verreck G; Brewster ME; Augustijns P
Int J Pharm; 2010 Aug; 395(1-2):182-97. PubMed ID: 20635475
[TBL] [Abstract][Full Text] [Related]
8. The use of biopartitioning micellar chromatography and immobilized artificial membrane column for in silico and in vitro determination of blood-brain barrier penetration of phenols.
Stępnik KE; Malinowska I
J Chromatogr A; 2013 Apr; 1286():127-36. PubMed ID: 23506703
[TBL] [Abstract][Full Text] [Related]
9. Prediction of blood-brain barrier permeation of α-adrenergic and imidazoline receptor ligands using PAMPA technique and quantitative-structure permeability relationship analysis.
Vucicevic J; Nikolic K; Dobričić V; Agbaba D
Eur J Pharm Sci; 2015 Feb; 68():94-105. PubMed ID: 25542610
[TBL] [Abstract][Full Text] [Related]
10. Analysing molecular polar surface descriptors to predict blood-brain barrier permeation.
Shityakov S; Neuhaus W; Dandekar T; Förster C
Int J Comput Biol Drug Des; 2013; 6(1-2):146-56. PubMed ID: 23428480
[TBL] [Abstract][Full Text] [Related]
11. Integrating in Silico and in Vitro Approaches To Predict Drug Accessibility to the Central Nervous System.
Zhang YY; Liu H; Summerfield SG; Luscombe CN; Sahi J
Mol Pharm; 2016 May; 13(5):1540-50. PubMed ID: 27015243
[TBL] [Abstract][Full Text] [Related]
12. Machine Learning Exploration of the Relationship Between Drugs and the Blood-Brain Barrier: Guiding Molecular Modification.
Yang Q; Fan L; Hao E; Hou X; Deng J; Xia Z; Du Z
Pharm Res; 2024 May; 41(5):863-875. PubMed ID: 38605261
[TBL] [Abstract][Full Text] [Related]
13. Predicting the Blood-Brain Barrier Permeability of New Drug-Like Compounds via HPLC with Various Stationary Phases.
Janicka M; Sztanke M; Sztanke K
Molecules; 2020 Jan; 25(3):. PubMed ID: 31979316
[TBL] [Abstract][Full Text] [Related]
14. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates.
Adenot M; Lahana R
J Chem Inf Comput Sci; 2004; 44(1):239-48. PubMed ID: 14741033
[TBL] [Abstract][Full Text] [Related]
15. Prediction of retention in hydrophilic interaction liquid chromatography using solute molecular descriptors based on chemical structures.
Taraji M; Haddad PR; Amos RI; Talebi M; Szucs R; Dolan JW; Pohl CA
J Chromatogr A; 2017 Feb; 1486():59-67. PubMed ID: 28049585
[TBL] [Abstract][Full Text] [Related]
16. Molecular properties determining unbound intracellular and extracellular brain exposure of CNS drug candidates.
Loryan I; Sinha V; Mackie C; Van Peer A; Drinkenburg WH; Vermeulen A; Heald D; Hammarlund-Udenaes M; Wassvik CM
Mol Pharm; 2015 Feb; 12(2):520-32. PubMed ID: 25496026
[TBL] [Abstract][Full Text] [Related]
17. Ligand and Structure-based Modeling of Passive Diffusion through the Blood-Brain Barrier.
Vilar S; Sobarzo-Sanchez E; Santana L; Uriarte E
Curr Med Chem; 2018; 25(9):1073-1089. PubMed ID: 29110594
[TBL] [Abstract][Full Text] [Related]
18. Applications of a blood-brain barrier technology platform to predict CNS penetration of various chemotherapeutic agents. 1. Anti-infective drugs.
Adenot M; Perriere N; Scherrmann JM; Lahana R
Chemotherapy; 2007; 53(1):70-2. PubMed ID: 17202814
[TBL] [Abstract][Full Text] [Related]
19. Role of breast cancer resistance protein (BCRP) as active efflux transporter on blood-brain barrier (BBB) permeability.
Garg P; Dhakne R; Belekar V
Mol Divers; 2015 Feb; 19(1):163-72. PubMed ID: 25502234
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling.
Luco JM
J Chem Inf Comput Sci; 1999; 39(2):396-404. PubMed ID: 10192950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
